EchoIQ Limited · ASX:EIQ
EchoIQ — Bell Potter Healthcare Conference 2026
22 slides from EchoIQ's conference presentation, Nov 17, 2026
Slide 1: Echo IQ Bell Potter Healthcare Conference 2026
rsonal use only ECHO IQ Bell Potter Healthcare Conference 2026 November 2026
Slide 2: Disclaimer and Forward-looking Statements
Disclaimer and Forward-looking Statements rsonal use only This presentation has been prepared by ECHOIQ LIMITED “EIQ”. This document contains This document does not constitute any part of any offer to sell, or the solicitation of an background information about EIQ current at the date of this presen
Slide 3: Disclaimer and Forward-looking Statements, cont.
Disclaimer and Forward-looking Statements, cont. rsonal use only This presentation may include forward-looking statements. Forward-looking statements are (vi) the Company's products are subject to extensive and ongoing U.S. federal and state regulation, only predictions and are subject to risks, unc
Slide 4: What we do
What we do Measurements captured across all echocardiogram images and maps them into a multi-dimensional AI model rsonal use only Examines all measurements (including ventricular, atrial, and The system What’s happening using aortic velocity pulmonary and right heart measurement data) to determine c
Slide 5: Management Team
Management Team Dustin Haines Chief Executive Officer Mr. Haines brings 25 years’ experience in leading global businesses in pharmaceuticals, biotechnology, and medical devices. Most recently, Mr Haines was head of Asia, Middle East, Turkey, and Russia for Gilead Sciences where he managed over US$1.
Slide 6: Clinical Advisors
Clinical Advisors Clinical Advisors: Echo IQ has unparalleled clinical/scientific advocates: Prof. David Playford Dr. Philippe Généreux MD MBBS, PhD, FRACP, Professor of rsonal use only • Globally recognized experts in cardiovascular medicine, Cardiology in the School of Medicine Interventional Card
Slide 7: Corporate Snapshot
Corporate Snapshot Company Overview Board of Directors Echo IQ Limited (ASX:EIQ) is an AI-driven cardiovascular diagnostics company focused on improving the detection of serious heart disease through advanced analysis of Steven Formica - Non-Executive Director rsonal use only echocardiograms (cardia
Slide 8: Echo: The Nexus of the Cardiology Funnel
Echo: The Nexus of the Cardiology Funnel Echo is not a step in the funnel; it IS the funnel. Everything upstream feeds it. Everything downstream flows from it. rsonal use only 150M ECGs Mass screening entry 20% 15% ECG → ECHO ECHO → CT CONVERSION 25M Echo Studies ESCALATION THE NEXUS HF to 1.5M CT A
Slide 9: Accessibility to US Echocardiographic Centers
Accessibility to US Echocardiographic Centers rsonal use only 9
Slide 10: Total Addressable Market
Total Addressable Market Combined Platform TAM: rsonal use only ~$3.89B Derived from two disease modules operating on existing echo infrastructures Heart Failure Module* Aortic Stenosis Module 10M HF detections HF TAM: AS TAM: 6M AS detections annually x $299 ~$2.99B ~$900M annually x $150 reimburse
Slide 11: EchoSolv AI processing
EchoSolv AI processing Capturing underlying data points of Echocardiogram rsonal use only 11
Slide 12: Why High Probability sAS Matters
Why High Probability sAS Matters rsonal use only The AI identifies a Severe AS Probability Patients in the Severe AS Probability group had: 5-year mortality rate similar to guideline-defined By analyzing the relationships among changes in: severe AS (69.1% vs. 64.4%) 6 • Valve flow, filling pressure
Slide 13: Recent Institutional News
Recent Institutional News Commercial Agreement Commercial Agreement Data Licensing Agreement rsonal use only • Commercial agreement to install • 3 Year Commercial agreement • 3 Year exclusive agreement to Aortic Stenosis solution to install EchoSolvHF (not yet conduct research and train AI EchoSolvA
Slide 14: Reimbursement Pathway
Reimbursement Pathway rsonal use only Aortic Stenosis Heart Failure (Not FDA Cleared) 0932T Cat III New Technology Code is 93799 Misc Code is an unlisted for noninvasive detection of heart cardiovascular procedure code used for Code Code failure using augmentative analysis of reporting new, unusual,
Slide 15: Strong & Accelerating Real-World Utilization
Strong & Accelerating Real-World Utilization YTD and Quarter. One platform. Transformational growth. rsonal use only YTD 2026 (Nine Months) Sep 2026 Quarter +193% 37,026 Sep Quarter YoY 12,345 Studies* Studies* Initial U.S. site deployments +406% Adoption accelerates Nine Months YoY EchoSolv AS is a
Slide 16: Strategic Partnership
Pro Medicus logo Strategic Partnership rsonal use only Pro Medicus Convertible Note Pro Medicus Reseller Agreement • Convertible note and option agreements • Heads of Agreement signed June 2026 executed (September quarter 2026) • Reseller agreement based on EchoSolv • $10m strategic investment as co
Slide 17: Clinical Evidence to Build Momentum
Clinical Evidence to Build Momentum Cardio-Oncology impact with Third-Party Evidence: Edwards EchoSolv AS in Real World rsonal use only EchoSolv HF PROGRESS Trial • The 12-month study included 2012 • Retrospective analysis evaluating the • TAVR in Patients with Moderate Aortic patients and evaluated
Slide 18: EchoSolv HF
EchoSolv HF rsonal use only What’s Done What’s Coming • FDA issued a Not Substantially Equivalent determination on • FDA response to the appeal; timing not strictly defined the initial EchoSolv HF 510(k) (announced 8 Sep 2026) • Possible outcomes: • Review found the matters cited relate to the stati
Slide 19: Strong Balance Sheet to Fund US Expansion
Strong Balance Sheet to Fund US Expansion September 2026 quarter rsonal use only Cash at 30 September 2026 Operating cash outflow, Sep quarter Estimated quarters of funding A$107.8m A$5.9m 18 A$100.0m on call deposit, A$7.8m at bank Staff A$3.0m; admin and corporate A$2.3m; other At the September-qu
Slide 20: Upcoming Milestones
Upcoming Milestones One scalable AI platform with multiple potential partners and pathways. Short Term Medium Term rsonal use only Initial U.S. flagship hospitals adopt EchoSolv AS & Major Hospital Group Additional Tier-1 Multiple globally recognised hospital systems HF, creating enterprise beachhea
Slide 21: Scaling Echo IQ – Expanding Conditions
Scaling Echo IQ – Expanding Conditions Echo IQ aims to become a multi-indication cardiovascular disease management platform 2028-2030 rsonal use only 2027 Pulmonary Hypertension Mitral Regurgitation (MR) 2026 Cardio-Oncology, • FDA submissions and clearances Hypertrophic Cardiomyopathy • Integration
Slide 22: Contact
rsonal use only Contact: Dustin Haines Chief Executive Officer Dustin.haines@echoiq.ai Henry Jordan Six Degrees Investor Relations Henry.jordan@sdir.com.au +61 (0) 431 271 538 22